Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

27.83 

0.05 0.2%

as of Sep 30 '22

52 Week Range:

27.78 48.52


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Equity (BVPS) 5.37
6.54
6.36
7.25
6.87
7.33
8.18
9.24
9.31
growth rate 21.8% -2.8% 14.0% -5.2% 6.7% 11.6% 13.0% 0.8%
Earnings BIT 65,289.00
67,457.00
81,704.00
75,468.00
108,042.00
103,403.00
109,848.00
97,443.00
116,664.00
growth rate 3.3% 21.1% -7.6% 43.2% -4.3% 6.2% -11.3% 19.7%
Avg.PE 35.95
37.24
31.25
26.03
13.45
15.58
15.58
29.59
growth rate 3.6% -16.1% -16.7% -48.3% 15.8% 0.0% 89.9%
ROA 4.34
6.42
4.25
4.22
5.35
5.64
8.69
7.23
7.21
5.96
growth rate 47.9% -33.8% -0.7% 26.8% 5.4% 54.1% -16.8% -0.3% -17.3%
ROE 7.03
11.90
7.30
7.19
9.34
10.84
17.56
12.73
11.73
9.59
growth rate 69.3% -38.7% -1.5% 29.9% 16.1% 62.0% -27.5% -7.9% -18.2%
ROIC 5.57
8.24
5.45
5.34
6.69
7.02
10.82
9.35
8.93
7.34
growth rate 47.9% -33.9% -2.0% 25.3% 4.9% 54.1% -13.6% -4.5% -17.8%
Cur. Ratio 1.63
2.48
1.93
3.17
2.22
1.41
2.30
2.79
2.17
2.48
growth rate 52.2% -22.2% 64.3% -30.0% -36.5% 63.1% 21.3% -22.2% 14.3%
Quick Ratio 1.08
1.50
1.22
2.19
1.50
0.87
1.62
1.77
1.41
1.56
growth rate 38.9% -18.7% 79.5% -31.5% -42.0% 86.2% 9.3% -20.3% 10.6%
Leverage 1.97
1.76
1.68
1.73
1.76
2.09
1.96
1.61
1.64
1.58
growth rate -10.7% -4.6% 3.0% 1.7% 18.8% -6.2% -17.9% 1.9% -3.7%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 93,788.00
100,126.00
103,486.00
103,036.00
108,078.00
121,932.00
128,462.00
133,473.00
129,280.00
136,776.00
growth rate 6.8% 3.4% -0.4% 4.9% 12.8% 5.4% 3.9% -3.1% 5.8%
Acct.Payable 37,515.00
38,147.00
38,484.00
36,294.00
38,451.00
67,515.00
81,476.00
88,044.00
83,528.00
81,545.00
growth rate 1.7% 0.9% -5.7% 5.9% 75.6% 20.7% 8.1% -5.1% -2.4%
Cur.Assets 286,955.00
310,985.00
412,458.00
374,746.00
349,183.00
410,912.00
398,722.00
460,607.00
523,966.00
558,713.00
growth rate 8.4% 32.6% -9.1% -6.8% 17.7% -3.0% 15.5% 13.8% 6.6%
Total Assets 771,032.00
832,814.00
992,073.00
901,685.00
1,021,405.00
1,078,981.00
1,120,790.00
1,241,355.00
1,351,192.00
1,473,693.00
growth rate 8.0% 19.1% -9.1% 13.3% 5.6% 3.9% 10.8% 8.9% 9.1%
Cash 78,201.00
95,618.00
129,679.00
149,672.00
105,388.00
167,832.00
122,982.00
166,898.00
200,770.00
205,251.00
growth rate 22.3% 35.6% 15.4% -29.6% 59.3% -26.7% 35.7% 20.3% 2.2%
Inventory 85,179.00
93,964.00
101,471.00
96,452.00
106,711.00
112,064.00
134,106.00
147,147.00
175,576.00
198,536.00
growth rate 10.3% 8.0% -5.0% 10.6% 5.0% 19.7% 9.7% 19.3% 13.1%
Cur.Liabilities 115,844.00
160,936.00
129,947.00
168,835.00
248,389.00
179,013.00
142,912.00
211,845.00
211,366.00
177,721.00
growth rate 38.9% -19.3% 29.9% 47.1% -27.9% -20.2% 48.2% -0.2% -15.9%
Liabilities 333,124.00
336,570.00
418,552.00
390,141.00
531,853.00
528,546.00
422,678.00
486,473.00
494,530.00
461,380.00
growth rate 1.0% 24.4% -6.8% 36.3% -0.6% -20.0% 15.1% 1.7% -6.7%
LT Debt 158,712.00
116,769.00
219,374.00
159,057.00
210,713.00
288,775.00
225,134.00
195,869.00
218,496.00
224,875.00
growth rate -26.4% 87.9% -27.5% 32.5% 37.1% -22.0% -13.0% 11.6% 2.9%
Equity 496,244.00
573,521.00
511,435.00
489,451.00
550,307.00
698,034.00
754,813.00
856,662.00
1,012,313.00
growth rate 15.6% -10.8% -4.3% 12.4% 26.8% 8.1% 13.5% 18.2%
Common Shares 760.00
760.00
760.00
776.00
802.00
774.00
38,716.00
38,716.00
38,716.00
38,716.00
38,716.00
growth rate 0.0% 0.0% 2.1% 3.4% -3.5% 4,902.1% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 25,715.00
39,933.00
37,342.00
28,209.00
29,838.00
31,866.00
39,326.00
62,316.00
62,318.00
53,515.00
growth rate 55.3% -6.5% -24.5% 5.8% 6.8% 23.4% 58.5% 0.0% -14.1%
Cash Dividends 9,683.00
11,012.00
13,200.00
14,518.00
15,839.00
19,555.00
20,507.00
21,155.00
23,455.00
growth rate 13.7% 19.9% 10.0% 9.1% 23.5% 4.9% 3.2% 10.9%
Cash From OA 50,270.00
96,259.00
73,110.00
80,303.00
80,862.00
114,562.00
93,571.00
117,479.00
121,485.00
141,467.00
growth rate 91.5% -24.1% 9.8% 0.7% 41.7% -18.3% 25.6% 3.4% 16.5%
FCF per Share 0.29
0.38
0.47
0.45
0.61
0.61
0.72
0.43
0.33
growth rate 31.0% 23.7% -4.3% 35.6% 0.0% 18.0% -40.3% -23.3%
FCF 31,935.00
17,796.00
51,366.00
32,085.00
47,391.00
44,344.00
73,240.00
39,207.00
33,995.00
38,361.00
87,952.00
growth rate -44.3% 188.6% -37.5% 47.7% -6.4% 65.2% -46.5% -13.3% 12.8% 129.3%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 402,294.00
467,359.00
489,506.00
525,026.00
514,164.00
587,775.00
599,481.00
628,897.00
613,842.00
703,303.00
growth rate 16.2% 4.7% 7.3% -2.1% 14.3% 2.0% 4.9% -2.4% 14.6%
Op.Income 47,067.00
65,289.00
67,457.00
81,704.00
75,468.00
108,042.00
103,403.00
109,848.00
97,443.00
116,664.00
growth rate 38.7% 3.3% 21.1% -7.6% 43.2% -4.3% 6.2% -11.3% 19.7%
IBT 52,906.00
64,045.00
76,920.00
74,981.00
106,630.00
102,709.00
106,466.00
97,060.00
114,500.00
growth rate 21.1% 20.1% -2.5% 42.2% -3.7% 3.7% -8.8% 18.0%
Net Income 47,067.00
34,096.00
38,470.00
50,676.00
54,225.00
91,295.00
79,470.00
85,211.00
77,268.00
88,813.00
growth rate -27.6% 12.8% 31.7% 7.0% 68.4% -13.0% 7.2% -9.3% 14.9%
EPS 31.82
61.90
44.89
49.56
63.18
71.38
121.03
104.97
112.61
102.11
growth rate 94.5% -27.5% 10.4% 27.5% 13.0% 69.6% -13.3% 7.3% -9.3%
Gross Profit 205,689.00
242,011.00
256,026.00
284,901.00
278,000.00
319,333.00
326,497.00
343,933.00
326,623.00
369,341.00
growth rate 17.7% 5.8% 11.3% -2.4% 14.9% 2.2% 5.3% -5.0% 13.1%
R&D 30,130.00
29,360.00
33,147.00
33,747.00
41,342.00
47,681.00
50,618.00
49,096.00
51,837.00
growth rate -2.6% 12.9% 1.8% 22.5% 15.3% 6.2% -3.0% 5.6%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 22,170.00
36,234.00
29,624.00
28,598.00
22,208.00
growth rate 63.4% -18.2% -3.5% -22.3%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 129,280.00
126,324.00
126,734.00
134,456.00
136,776.00
growth rate -2.3% 0.3% 6.1% 1.7%
Acct.Payable 83,528.00
76,291.00
72,700.00
71,788.00
81,545.00
growth rate -8.7% -4.7% -1.3% 13.6%
Cur.Assets 523,966.00
510,698.00
529,532.00
543,844.00
558,713.00
growth rate -2.5% 3.7% 2.7% 2.7%
Total Assets 1,351,192.00
1,339,556.00
1,368,977.00
1,401,522.00
1,473,693.00
growth rate -0.9% 2.2% 2.4% 5.2%
Cash 200,770.00
186,745.00
202,927.00
204,905.00
205,251.00
growth rate -7.0% 8.7% 1.0% 0.2%
Inventory 175,576.00
178,303.00
180,446.00
185,893.00
198,536.00
growth rate 1.6% 1.2% 3.0% 6.8%
Cur.Liabilities 211,366.00
182,989.00
185,828.00
187,885.00
177,721.00
growth rate -13.4% 1.6% 1.1% -5.4%
Liabilities 494,530.00
465,552.00
465,020.00
465,618.00
461,380.00
growth rate -5.9% -0.1% 0.1% -0.9%
LT Debt 218,496.00
218,173.00
218,781.00
220,488.00
224,875.00
growth rate -0.2% 0.3% 0.8% 2.0%
Equity 856,662.00
874,004.00
903,957.00
935,904.00
1,012,313.00
growth rate 2.0% 3.4% 3.5% 8.2%
Common Shares 38,716.00
38,716.00
38,716.00
38,716.00
38,716.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 14,952.00
14,073.00
13,824.00
12,930.00
12,688.00
growth rate -5.9% -1.8% -6.5% -1.9%
Cash Dividends 78.00
11,165.00
170.00
12,067.00
53.00
growth rate 14,214.1% -98.5% 6,998.2% -99.6%
Cash From OA 48,014.00
29,904.00
36,831.00
31,622.00
43,110.00
growth rate -37.7% 23.2% -14.1% 36.3%
FCF 33,062.00
15,831.00
23,007.00
18,692.00
30,422.00
growth rate -52.1% 45.3% -18.8% 62.8%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 165,214.00
171,716.00
172,921.00
178,844.00
179,821.00
growth rate 3.9% 0.7% 3.4% 0.6%
Op.Income 22,170.00
36,234.00
29,624.00
28,598.00
22,208.00
growth rate 63.4% -18.2% -3.5% -22.3%
IBT 22,131.00
36,020.00
29,261.00
27,762.00
21,456.00
growth rate 62.8% -18.8% -5.1% -22.7%
Net Income 18,667.00
27,895.00
22,092.00
21,708.00
17,117.00
growth rate 49.4% -20.8% -1.7% -21.2%
Gross Profit 85,355.00
94,259.00
91,986.00
92,596.00
90,500.00
growth rate 10.4% -2.4% 0.7% -2.3%
R&D 49,096.00
51,837.00
51,837.00
51,837.00
51,837.00
growth rate 5.6% 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (68.46)

YOY Growth Grade:

D (43.10)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 30.89 29.86
EPS / Growth 0.93

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 13.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 13.6% 13.6% 13.6%
Future PE 0.01 19.39 19.39
Future EPS 3.35 3.35 3.35
Value Price
MOS %
0.01
-100.0%
16.05
-42.3%
16.05
-42.3%
MOS Price 0.00 8.02 8.02
IRT 11.90 11.90 11.90

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.